Document:

EXHIBIT
        4.12

        
        AMENDMENT NO. 
        1

        THIS
        AGREEMENT made the 20th day of March, 2008.

        
        BETWEEN:

        
        ONCOLYTICS BIOTECH INC.

        
        (“Oncolytics”)

         

        - and
        -

         

        MARY ANN
        DILLAHUNTY

        (the
        “Employee”)

        
        WHEREAS Oncolytics and the Employee entered into an Employment Agreement
        dated the 12th day of January, 2007, as amended pursuant to Amending Agreement #1
        dated December 3, 2007 (the “Employment Agreement)”

        
        AND WHEREAS the parties wish to amend the Employment Agreement;

        
        NOW THEREFORE the parties agree as follows:

        
        Section 1 –Amendments

        
        The Employment Agreement is hereby amended:

        	
                     

                	
                    
                    (a)

                	
                    
                    by replacing Section 3(1) with the following:

                

        
        “Commencing January 1, 2008, Oncolytics shall pay to the Employee
        a salary of TWO HUNDRED THIRTY-ONE THOUSAND SEVEN HUNDRED AND FIFTY UNITED STATES DOLLARS
        (US$231,750.00) per annum, exclusive of bonuses, benefits and other compensation, payable
        in equal installments of NINETEEN THOUSAND THREE HUNDRED TWELVE UNITED STATES DOLLARS AND
        FIFTY CENTS (US$19,312.50) on the last day of each month.”

        	
                     

                	
                    
                    (b)

                	
                    
                    by replacing Section 4 with the following:

                

        
        “The Employee shall be entitled to payment in lieu of employment
        benefits (medical, dental, etc,) of a total of TWENTY EIGHT THOUSAND SEVEN HUNDRED
        AND

        

        
        
        

        

        
         

        
        FIFTY-FIVE UNITED STATES DOLLARS (US$28,755.00) annually, payable pro rata
        with the Employee’s monthly payment of salary.”

        
        Section 2 - Effective Date

         

        	
                    
                    (1)

                	
                    
                    This Amending Agreement shall be effective from and after
                    January 1, 2008.

                

        
        (2)          
        In all other respects the parties confirm that the Employment Agreement, as
        amended, shall remain in full force and effect.

        
        IN WITNESS WHEREOF the parties have executed this Agreement as of the day
        and year first above written.

        
        ONCOLYTICS BIOTECH INC.

        
         

        
        Per:    
         /s/ Brad
        Thompson                                   

        	
                    
                     

                	
                    
                    Brad Thompson

                	
                    
                     

                
	
                    
                     

                	
                    
                    President & CEO

                

        
         

        
         

        
        Per:    
         /s/ Doug
        Ball                      
                            

        	
                    
                     

                	
                    
                    Doug Ball

                	
                    
                     

                
	
                    
                     

                	
                    
                    Chief Financial Officer

                

         

        	
                    
                                                              
                                                    

                	
                    
                     

                
	
                    
                    /s/ T. Gene
                    Dillahunty                                       

                	
                    
                    /s/ Mary Ann
                    Dillahunty                               

                
	
                    
                    WITNESS

                	
                	
                    
                    MARY ANN DILLAHUNTY

                

             
        -2-EXHIBIT
        4.13

        
        AMENDMENT NO. 1

        THIS
        AGREEMENT made the 28th day of March, 2008.

        
        BETWEEN:

        
        ONCOLYTICS BIOTECH INC.

        
        (“Oncolytics”)

         

        - and
        -

         

        
        KARL L. METTINGER, M.D., Ph.D

        (the
        “Employee”)

        
        WHEREAS Oncolytics and the Employee entered into an Executive Employment
        Agreement dated the 29th day of May, 2007 (the “Employment
        Agreement)”

        
        AND WHEREAS the parties wish to amend the Employment Agreement;

        
        NOW THEREFORE the parties agree as follows:

        
        Section 1 –Amendments

        
        The Employment Agreement is hereby amended:

        	
                     

                	
                    
                    (a)

                	
                    
                    by replacing Section 3(1) with the following:

                

        
        “Commencing January 1, 2008, Oncolytics shall pay to the Employee
        a salary of THREE HUNDRED EIGHTEEN THOUSAND TWO HUNDRED AND SEVENTY UNITED STATES DOLLARS
        (US$318,270.00) per annum, exclusive of bonuses, benefits and other compensation, payable
        in equal installments of TWENTY-SIX THOUSAND FIVE HUNDRED TWENTY-TWO UNITED STATES DOLLARS
        AND FIFTY CENTS (US$26,522.50) on the last day of each month.”

        	
                     

                	
                    
                    (b)

                	
                    
                    by replacing Section 4 with the following:

                

        
         

        
        “The Employee shall be entitled to payment in lieu of employment
        benefits (medical, dental, etc,) of a total of THIRTY EIGHT THOUSAND EIGHT HUNDRED AND
        NINETY-SIX UNITED STATES DOLLARS AND TWENTY CENTS (US$38,896.20)
        annually, payable pro rata with the Employee’s monthly payment of
        salary.”

         

        
        Section 2 - Effective Date

        	
                    
                    (1)

                	
                    
                    This Amending Agreement shall be effective from and after
                    January 1, 2008.

                

        
        (2)          
        In all other respects the parties confirm that the Employment Agreement, as
        amended, shall remain in full force and effect.

        
        IN WITNESS WHEREOF the parties have executed this Agreement as of the day
        and year first above written.

        
        ONCOLYTICS BIOTECH INC.

        
         

        
        Per:    
         /s/ Brad
        Thompson                        
              

        	
                    
                     

                	
                    
                    Brad Thompson President & CEO

                

        
         

        
         

        
        Per:    
         /s/ Doug
        Ball                                          

        	
                    
                     

                	
                    
                    Doug Ball

                	
                    
                     

                
	
                    
                     

                	
                    
                    Chief Financial Officer

                

         

        	
                    
                                                              
                                                    

                	
                    
                     

                
	
                    
                    /s/ Debbie
                    McClusky                                           

                	
                    
                    /s/ Karl L.
                    Mettinger                                  

                
	
                    
                    WITNESS

                	
                	
                    
                    KARL L. METTINGER, M.D., Ph.D.

                

        -2-EXHIBIT
        4.14

        
        AMENDMENT NO. 
        2

        THIS
        AGREEMENT made the 31st day of March, 2008.

        
        BETWEEN:

        
        ONCOLYTICS BIOTECH INC.

        
        (“Oncolytics”)

         

        - and
        -

         

        GEORGE
        GILL, M.D.

        
        (“Gill”)

        
        WHEREAS Oncolytics and Gill entered into a Services Agreement dated the 18th
        day of October, 2002, as amended by Amending Agreement No. 1 dated January 6,
        2005 (the “Services Agreement)”

        
        AND WHEREAS the parties wish to amend the Services Agreement;

        
        NOW THEREFORE the parties agree as follows:

        Section
        1 – Amendments

        
        The Services Agreement is hereby amended by revising the first paragraph of
        Schedule B as follows;

        
        “Commencing January 1, 2008, Oncolytics shall pay to Gill an
        annual retainer of ONE HUNDRED MINE THOUSAND TWO HUNDRED AND SEVENTY-TWO UNITED STATES
        DOLLARS AND SEVENTY CENTS (US$109,272.70) per annum, payable in equal monthly installments
        of NINE THOUSAND ONE HUNDRED SIX UNITED STATES DOLLARS AND SIX CENTS (US$9,106.06) on the
        last day of each month.”

        Section
        2 - Effective Date

        	
                    
                    (1)

                	
                    
                    This Amending Agreement shall be effective from and after
                    January 1, 2008.

                

        
        (2)          
        In all other respects the parties confirm that the Services Agreement, as
        amended, shall remain in full force and effect.

         

        

        
        
        

        

         

         

        
        IN WITNESS WHEREOF the parties have executed this Agreement as of the day
        and year first above written.

        
        ONCOLYTICS BIOTECH INC.

        
         

        
        Per:    
         /s/ Brad
        Thompson                                                  

        	
                    
                     

                	
                    
                    Brad Thompson

                	
                    
                     

                
	
                    
                     

                	
                    
                    President & CEO

                

        
         

        
         

        
        Per:    
         /s/
        Doug Ball                                                          

        	
                    
                     

                	
                    
                    Doug Ball

                	
                    
                     

                
	
                    
                     

                	
                    
                    Chief Financial Officer

                

         

        	
                    
                                                              
                                                    

                	
                    
                     

                
	
                    
                    /s/ Karyn C.
                    Gill                                            

                	
                    
                    /s/ George
                    Gill                                                        

                
	
                    
                    WITNESS

                	
                	
                    
                    GEORGE GILL, M.D.

                

         

         

        -2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]